Head and Neck Cancer Center
Contact Person:
Olivia Ksoll
Tel.: 0391-6724779
E-Mail:
Disease/Center |
Name of Study |
Short Description |
| Head-Neck | IMSTAR HN |
National, multicenter, prospective, randomized controlled phase III study aimed to evaluate the efficacy of immunotherapy alone (nivolumab) and combined immunotherapy (nivolumab and ipilimumab) as maintenance therapy after adjuvant radio(chemo)therapy for resectable head and neck cancer. The potential superiority of immunotherapy will be elucidated by comparison to a standard therapy arm. |
| Head-Neck | HANNA |
National, multicenter, prospective, non-interventional study (NIS) with nivolumab (BMS936558) in patients with squamous cell carcinoma of the head and neck who have tumor progression during or after platinum-based therapy. The objective of the study is to evaluate the efficacy and safety of nivolumab in clinical practice in Germany in head and neck cancer with progression under platinum-based treatment.
|